&nbsp;

OH-Indigenous-cancer-strategy_EN.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy_FR.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy-executive-summary_EN.pdf

New

Dec 2025

Document

OH-Indigenous-cancer-strategy-executive-summary_FR.pdf

New

Dec 2025

Regimen

OXALRALT+BEVA

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

New Drug Funding Program

Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2025

Statistical Reports

Ontario Cancer Statistics 2024

Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....

Feb 2025

Document

OH-cancer-screening-toolkit-complete-print

New

Dec 2025

Ontario Lung Screening Program Locations

Lung cancer screening through the Ontario Lung Screening Program is available for people who qualify at the following hospitals in Ontario. People...

Gestion de l'essoufflement chez les personnes atteintes de cancer

Ontario Cancer Registry SEER*Stat Package

The Ontario Cancer Registry SEER*Stat Package contains de-identified Ontario cancer data files derived from the Ontario Cancer Registry, the SEER*...

Regimen

GEMOX+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma